Investors & Media

Ionis reports first quarter 2024 financial results

WAINUA TM  launch on track; EU and Canada approval decisions expected this year Olezarsen NDA submitted to FDA for FCS ; preparing EU regulatory submission Positive Phase 3 donidalorsen data for HAE; preparing regulatory submissions On track to achieve 2024 financial guidance CARLSBAD, Calif.

Read more
You are now leaving https://www.ionispharma.com to visit